Life Sciences Tools and Services
Company Overview of Personalis, Inc.
Personalis, Inc. provides human genome analysis services for clinical medicine. It offers genome sequencing and interpretation services for research and medical communities. The company was incorporated in 2011 and is based in Palo Alto, California with a subsidiary operation in the United Kingdom.
530 Lytton Avenue
Palo Alto, CA 94301
Founded in 2011
Key Executives for Personalis, Inc.
Compensation as of Fiscal Year 2013.
Personalis, Inc. Key Developments
Inova Translational Medicine Institute and Personalis, Inc. Announce Partnership to Advance Genomic Medicine
Mar 27 14
Inova Translational Medicine Institute and Personalis, Inc. announced a partnership to advance genomic medicine for Inova's patient population. Personalis will collaborate with Inova on whole genome analysis and interpretation for undiagnosed syndromes in an effort to provide patients and their families an answer for these difficult cases. For patients with conditions of suspected genomic etiology where no clear answer has been found, the teams will work together to find answers. ITMI will perform WGS in an effort to uncover the genomic cause of the disease. Personalis will provide data analysis and clinical interpretation of the results to identify any likely genetic causes. The Inova team will then review the results and determine how best to use the genomic information in the management of patients' care at Inova Fairfax Hospital.
Personalis Announces Appointments to Clinical and Scientific Advisory Board
Jan 29 14
Personalis, Inc. announced that Deanna Church, Ph.D., has joined its R&D team, and Robert Nussbaum, M.D., Professor of Medicine and Chief of the Division of Genomic Medicine at UCSF, has joined its Clinical and Scientific Advisory Board. Dr. Nussbaum will bring his deep expertise in medical genetics to guide development of Personalis' next-generation sequencing (NGS) based clinical services. Dr. Church comes to Personalis from the NCBI where she helped lead development of the newest Human Reference GRCh38 as well as genomic tools used by scientists worldwide.
Personalis Announces Launch of Early Access Program to the Personalis ACE Clinical Exome
Oct 21 13
Personalis, Inc. announced the launch of an early access program to the Personalis ACE Clinical Exome(TM), a single test that integrates enhanced exome sequencing with genome-wide structural variant detection to increase diagnostic yield. "Personalis' goal is to improve diagnostic yield while decreasing overall cost and turnaround time compared with traditional serial genetic testing. The ACE Clinical Exome(TM) leverages the latest advances in Personalis' ACE (Accuracy and Content Enhanced) platform technology. The ACE platform combines: ACE Sequencing for improved accuracy and coverage over standard clinical exome offerings; the advanced ACE Pipeline for best-in-class alignment and variant calling, incorporating an enhanced reference sequence for improved accuracy; and ACE Annotation, with content from proprietary disease variant and pharmacogenomics databases integrated with over 40 additional public and commercial databases, to provide superior gene-phenotype associations and increased diagnostic yield. Each prioritized variant is examined in detail by Personalis' clinical team of physicians, genetic counselors, and bioinformaticians. Results are presented in an intuitive and actionable report, created by clinicians for clinicians, so that providers can rapidly understand and assess the findings. The company is currently receiving projects from clinicians as part of an early access program.
Similar Private Companies By Industry
Recent Private Companies Transactions
October 1, 2013